A federal judge has ruled that Mircera, a Roche anemia drug that would compete with Amgen's Epogen and Aranesp, violates an Amgen patent.
一次联邦审判认定Mircera,一个罗氏生产的用于同安进的Epogen和Aranesp竞争的药物,触犯了安进的专利权。
Among the patients who received Aranesp to treat their anemia, 14% had died after three years, compared with 9.8% of those who did not receive Aranesp.
在这些病人中,应用Aranesp治疗贫血(化疗引起)的病人三年死亡率14%,而不用Aranesp的病人三年死亡率9.8%。
应用推荐